当前位置: X-MOL 学术Blood Cancer J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2024-05-27 , DOI: 10.1038/s41408-024-01072-0
Yishan Ye 1 , Myriam Labopin 2 , Jia Chen 3 , Depei Wu 3 , Tobias Gedde-Dahl 4 , Didier Blaise 5 , Gérard Socie 6 , Edouard Forcade 7 , Urpu Salmenniemi 8 , Sébastien Maury 9 , Jurjen Versluis 10 , Ali Bazarbachi 11 , Arnon Nagler 12 , Eolia Brissot 2, 13 , Lin Li 1 , Yi Luo 1 , Jimin Shi 1 , Fabio Ciceri 14 , He Huang 1 , Mohamad Mohty 2, 13 , Norbert Claude Gorin 2, 13
Affiliation  



中文翻译:


对于 KMT2A 重排的 AML 患者,HAPLO 与 MSD 或 MUD HCT 相比复发率更低:来自全球委员会和 EBMT ALWP 的一项研究


更新日期:2024-05-27
down
wechat
bug